Comparative Pharmacology
Head-to-head clinical analysis: FILSPARI versus LOSARTAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FILSPARI versus LOSARTAN.
FILSPARI vs Losartan
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FILSPARI (sparsentan) is an endothelin receptor antagonist (ERA) and angiotensin II receptor blocker (ARB) with high affinity for the endothelin type A (ETA) receptor and angiotensin II type 1 (AT1) receptor. It reduces proteinuria in IgA nephropathy by inhibiting endothelin-1 mediated vasoconstriction, inflammation, and fibrosis, and by blocking angiotensin II mediated effects.
Losartan is an angiotensin II receptor blocker (ARB) that selectively and competitively inhibits the binding of angiotensin II to the AT1 receptor, thereby antagonizing vasoconstriction, aldosterone secretion, and renal sodium reabsorption, leading to reduced blood pressure.
200 mg orally once daily, with or without food.
Losartan 50 mg orally once daily; may increase to 100 mg once daily based on blood pressure response.
None Documented
None Documented
Clinical Note
moderateLosartan + Etacrynic acid
"The risk or severity of adverse effects can be increased when Losartan is combined with Etacrynic acid."
Clinical Note
moderateLosartan + Furosemide
"The risk or severity of adverse effects can be increased when Losartan is combined with Furosemide."
Clinical Note
moderateLosartan + Bumetanide
"The risk or severity of adverse effects can be increased when Losartan is combined with Bumetanide."
Clinical Note
moderateLosartan + Benzydamine
Terminal half-life ~30 hours in healthy subjects, supporting once-daily dosing.
Terminal half-life: 6-9 hours (losartan), 6-9 hours (active metabolite E-3174); clinical context: once-daily dosing is sufficient due to prolonged receptor binding
Primarily hepatic metabolism; <1% excreted unchanged in urine. ~59% of dose recovered in feces and ~27% in urine as metabolites.
Renal: 50% (parent drug and active metabolite), Biliary/Fecal: 50%
Category C
Category D/X
Endothelin Receptor Antagonist / ARB
ARB
"The risk or severity of adverse effects can be increased when Losartan is combined with Benzydamine."